Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Authors
Schambach, AxelBohne, J
Chandra, Saurabh
Will, Elke
Margison, Geoffrey P
Williams, David A
Baum, Christopher
Affiliation
Department of Hematology, Hemostaseology, and Oncology, Hannover Medical School, Germany.Issue Date
2006-02
Metadata
Show full item recordAbstract
Severe adverse events related to insertional mutagenesis have reinforced interest in self-inactivating (SIN) retroviral vectors lacking enhancer-promoter sequences in the long terminal repeats (LTRs). Here, we have compared the potency of gammaretroviral and lentiviral vectors expressing the P140K mutant of O(6)-methylguanine-DNA methyltransferase (MGMT). MGMT-P140K is a clinically relevant selection marker that mediates a strong survival advantage in hematopoietic cells exposed to alkylating agents. We designed gammaretroviral and lentiviral vectors that contained identical enhancer-promoter sequences located either in the LTR or downstream of the packaging region, for internal initiation of transcription from SIN backbones. Gammaretroviral vectors with intact LTRs containing enhancer-promoter sequences showed both higher titers and higher expression levels than the lentiviral counterparts, likely a result of suboptimal RNA processing of the lentiviral leader region. In the SIN context, gammaretroviral and lentiviral vectors with comparable internal cassettes had similar expression properties. Interestingly, gammaretroviral SIN vectors pseudotyped with RD114/TR had a higher transduction efficiency on proliferating human CD34(+) cells than lentiviral counterparts. These results encourage further investigations into the formation of retroviral hybrid vectors that combine the desired properties of high efficiency and increased biosafety.Citation
Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. 2006, 13 (2):391-400 Mol. Ther.Journal
Molecular TherapyDOI
10.1016/j.ymthe.2005.08.012PubMed ID
16226060Type
ArticleLanguage
enISSN
1525-0016ae974a485f413a2113503eed53cd6c53
10.1016/j.ymthe.2005.08.012
Scopus Count
Collections
Related articles
- Mechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors.
- Authors: Maetzig T, Galla M, Brugman MH, Loew R, Baum C, Schambach A
- Issue date: 2010 Mar
- A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines.
- Authors: Richard E, Géronimi F, Lalanne M, Ged C, Redonnet-Vernhet I, Lamrissi-Garcia I, Gerson SL, de Verneuil H, Moreau-Gaudry F
- Issue date: 2003 Sep
- Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.
- Authors: Schambach A, Mueller D, Galla M, Verstegen MM, Wagemaker G, Loew R, Baum C, Bohne J
- Issue date: 2006 Nov
- Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
- Authors: Kramer BA, Lemckert FA, Alexander IE, Gunning PW, McCowage GB
- Issue date: 2006 Sep
- Towards hematopoietic stem cell-mediated protection against infection with human immunodeficiency virus.
- Authors: Schambach A, Schiedlmeier B, Kühlcke K, Verstegen M, Margison GP, Li Z, Kamino K, Bohne J, Alexandrov A, Hermann FG, von Laer D, Baum C
- Issue date: 2006 Jul